Requiring an Amyloid-Β1-42 Biomarker for Prodromal Alzheimer's Disease or Mild Cognitive Impairment Does Not Lead to More Efficient Clinical Trials

Alzheimer's and Dementia - United States
doi 10.1016/j.jalz.2010.07.004

Related search